XML 46 R28.htm IDEA: XBRL DOCUMENT
v3.24.0.1

BUSINESS SEGMENT INFORMATION | 12 Months Ended
--- | ---
Dec. 31, 2023
Segment Reporting [Abstract] |
BUSINESS SEGMENT INFORMATION | BUSINESS SEGMENT INFORMATION The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's CODM, assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers within its primary customer channels - physicians, hospitals, and patients and consumers. The DIS business accounted for greater than 95% of net revenues in 2023, 2022 and 2021. All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses offer solutions for insurers and offer solutions for healthcare providers and payers. As of December 31, 2023, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States. The following table is a summary of segment information for the years ended December 31, 2023, 2022 and 2021. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2.
| 2023 |  | 2022 |  | 2021
Net revenues: |  |  |  |  |
DIS business | $ | 8,976 |  |  | $ | 9,609 |  |  | $ | 10,494 |
All other operating segments | 276 |  |  | 274 |  |  | 294 |
Total net revenues | $ | 9,252 |  |  | $ | 9,883 |  |  | $ | 10,788 |
Operating earnings (loss): |  |  |  |  |
DIS business | $ | 1,547 |  |  | $ | 1,704 |  |  | $ | 2,646 |
All other operating segments | 34 |  |  | 20 |  |  | 29 |
General corporate activities | (319) |  |  | (296) |  |  | (294) |
Total operating income | 1,262 |  |  | 1,428 |  |  | 2,381 |
Non-operating (expense) income, net | (132) |  |  | (193) |  |  | 218 |
Income before income taxes and equity in earnings of equity method investees | 1,130 |  |  | 1,235 |  |  | 2,599 |
Income tax expense | (248) |  |  | (264) |  |  | (597) |
Equity in earnings of equity method investees, net of taxes | 26 |  |  | 44 |  |  | 78 |
Net income | 908 |  |  | 1,015 |  |  | 2,080 |
Less: Net income attributable to noncontrolling interests | 54 |  |  | 69 |  |  | 85 |
Net income attributable to Quest Diagnostics | $ | 854 |  |  | $ | 946 |  |  | $ | 1,995 |
Depreciation and amortization expense for the years ended December 31, 2023, 2022 and 2021 were as follows:
| 2023 |  | 2022 |  | 2021
DIS business | $ | 319 |  |  | $ | 305 |  |  | $ | 294 |
All other operating segments | 11 |  |  | 12 |  |  | 10 |
General corporate | 109 |  |  | 120 |  |  | 104 |
Total depreciation and amortization | $ | 439 |  |  | $ | 437 |  |  | $ | 408 |
Capital expenditures for the years ended December 31, 2023, 2022 and 2021 were as follows:
| 2023 |  | 2022 |  | 2021
DIS business | $ | 398 |  |  | $ | 384 |  |  | $ | 379 |
All other operating segments | 8 |  |  | 19 |  |  | 14 |
General corporate | 2 |  |  | 1 |  |  | 10 |
Total capital expenditures | $ | 408 |  |  | $ | 404 |  |  | $ | 403 |
The approximate percentage of net revenues by major service for the years ended December 31, 2023, 2022 and 2021 was as follows:
| 2023 |  | 2022 |  | 2021
Routine clinical testing and other services | 51 | % |  | 44 | % |  | 40 | %
COVID-19 testing services | 2 |  |  | 15 |  |  | 26 |
Gene-based and esoteric (including advanced diagnostics) testing services | 38 |  |  | 32 |  |  | 26 |
Anatomic pathology testing services | 6 |  |  | 6 |  |  | 5 |
All other | 3 |  |  | 3 |  |  | 3 |
Net revenues | 100 | % |  | 100 | % |  | 100 | %
The approximate percentage of net revenues by customer channel for the years ended December 31, 2023, 2022 and 2021 was as follows:
| 2023 |  | 2022 |  | 2021
Physician lab services | 66 | % |  | 68 | % |  | 69 | %
Hospital lab services | 21 |  |  | 18 |  |  | 17 |
Other DIS | 10 |  |  | 11 |  |  | 11 |
Total DIS revenues | 97 |  |  | 97 |  |  | 97 |
DS revenues | 3 |  |  | 3 |  |  | 3 |
Total net revenues | 100 | % |  | 100 | % |  | 100 | %
Physician lab services includes net revenues for physicians including those associated with ACOs and FQHCs.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration